Spectral Medical Inc.

TSX:EDT.TO

Medical - Diagnostics & Research

Healthcare
$1.04 -1.45%

-$0.02 today

Market cap
$306.00M
Beta
0.23
P/E (TTM)
-10.5
EPS (TTM)
-$0.13
52W Low $0.77High $1.84

Volume 0.02M

Average 0.06M

EDT.TO Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Spectral Medical Inc.TSX: EDT.TO

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of CA$2.93M rose 2245.6% year over year, ahead of the +344.3% change in trailing-twelve-month cost of revenue. Sequentially, it rose 91.0% from the prior quarter. Over 3 fiscal years it compounded at +123.1% a year.

Context

  • Cost of revenue amounted to 311.1% of revenue in FY2025, up 255.7 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +2245.6% holds above the trailing-twelve-month pace of +344.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$2.93M+91.0% QoQ
Last fiscal yearDec 2025
CA$7.6M+499.2% YoY
LTMMar 2026
CA$4.95M+344.3% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2245.6%——
1 year+499.2%——
3-year CAGR+123.1%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

CAD · from the income statement

Latest · FY2025
7.6M CAD
Year-over-year change
+499.2%
4-year CAGR
+73.8%

Cost of Revenue vs competitors

How EDT.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +344.3% is the highest of 8, against a peer median of +32.6%.
  • Cost of revenue amounts to 179.2% of revenue for EDT.TO, versus a peer median of 34.4%.
EDT.TO Competitors
Cost of Revenue for EDT.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$237.39M CAD+25.3%-20.7%76.4%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$218.14M CAD+40.1%+0.7%68.5%
KSI.TOKneat.com, Inc.LTM Mar 2026CA$26.53M CAD+101.5%+46.4%39.9%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$12.97M USD+17.0%+63.9%25.5%
PRN.TOProfound Medical Corp.LTM Mar 2026$5.43M USD+43.5%+9.4%29.0%
EDT.TOSpectral Medical Inc.LTM Mar 2026CA$4.95M CAD+344.3%+123.1%179.2%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$3.99M USD+32.6%+252.4%7.8%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$281.1K USD+30.3%+7.8%—
Peer median (excluding EDT.TO) —+32.6%+9.4%34.4%

Competitors are the stored peer set for EDT.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2M1.67M1.6M2.29M2.44M
Cost of Revenue832K684K936K1.27M7.6M
Gross Profit1.16M983K662K1.02M(5.16M)
Gross Margin58.3%59.0%41.4%44.5%-211.1%
Research & Development004.68M3.97M4.33M
Selling, General & Admin7.01M8.64M11.29M11.62M11.73M
Operating Expenses7.86M9.43M12.08M13.02M6.53M
Depreciation & Amortization294K272K218K251K250K
EBITDA(6.38M)(7.18M)(13.96M)(11.97M)(11.44M)
EBITDA Margin-319.4%-430.7%-873.3%-523.5%-468.3%
Operating Income(6.66M)(8.45M)(11.42M)(12M)(11.69M)
Operating Margin-333.5%-506.7%-714.7%-524.8%-478.5%
Interest Income00005.39M
Interest Expense28K176K1.33M3.18M5.16M
Other Income / Expenses(40K)819K(4.09M)(3.4M)(36M)
Income Before Tax(6.96M)(7.63M)(15.51M)(15.4M)(47.69M)
Pre-Tax Margin-348.6%-457.6%-970.4%-673.4%-1952.9%
Income Tax Expense00000
Net Income(8.79M)(11.28M)(15.66M)(15.4M)(47.69M)
Net Margin-440.1%-676.7%-980.1%-673.8%-1953.0%
EPS (Basic)(0.03)(0.04)(0.06)(0.05)(0.17)
EPS (Diluted)(0.03)(0.04)(0.06)(0.05)(0.17)
Weighted Avg Shares252.46M269.84M278.56M281.08M287.21M
Weighted Avg Shares (Diluted)252.46M269.84M278.56M281.08M287.21M

Spectral Medical Inc.

TSX:EDT.TO

Intrinsic Alpha fair value

Locked

Current Price

$1.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.